Bharat Biotech cuts malaria vaccine rates under GAVI-UNICEF agreement

Bharat Biotech International Limited has announced a significant price reduction for its malaria vaccine as part of a supply agreement with UNICEF, supported by the GAVI Alliance. The move aims to improve vaccine accessibility and affordability in countries where malaria remains a major public health challenge.

Under the arrangement, the pharmaceutical company has committed to providing its malaria vaccine at substantially reduced rates to eligible nations, particularly in sub-Saharan Africa and South Asia where disease burden remains high. The GAVI backing provides additional financial support and procurement coordination to facilitate widespread distribution.

The agreement reflects growing international focus on malaria elimination through vaccination, particularly following regulatory approvals for new vaccine candidates in recent years. By aligning with GAVI and UNICEF procurement mechanisms, Bharat Biotech positions itself as a key supplier for immunization programs targeting malaria-endemic regions.

The initiative is expected to facilitate vaccine rollout in low and middle-income countries over the coming years, though specific pricing details and implementation timelines remain subject to ongoing coordination between the parties. The arrangement underscores India's role as a major vaccine manufacturer addressing global health priorities.